StatusThe thesis was presented on the 4 July, 2012
Approved by NCAA on the 9 October, 2012
Abstract– 0.58 Mb / in romanian
The thesis has 120 pages and consists of: introduction, 3 chapters, conclusions, practical recommendations, reference of 192 sources, 24 tables, and 31 figures. The results are published in 11 scientific papers.
Aim of the study: to assess the impact on insulin resistance and parameters of diastolic function under long-term medication with angiotensin receptor blocker II - Eprosartan versus angiotensin converting enzyme inhibitor II - Ramipril.
Objectives: to appreciate the interrelation insulin resistance – diastolic dysfunction; to estimate the evolution of diastolic function parameters in correlation with medication; to assess the action of Eprosartan versus Ramipril on insulin resistance; to determine the correlation among the arterial blood pressure, insulin resistance and the parameters of diastolic function.
Innovation and originality: the action of a new ARB II – Eprosartan was observed on: diastolic function, insulin resistance. It was estimated the impact on the interrelation between insulin resistance - diastolic dysfunction in patients with essential hypertension.
Scientific problem solved in thesis: it was documented the superiority of ARB II – Eprosartan in improving the diastolic function and insulin resistance parameters, in comparison with ACE II.
Theoretical significance: it was established the importance of insulin resistance parameters assessment, namely, in the presence of diastolic dysfunction and the evolution prognosis in hypertensive patients exposed to long-term medication with ARB II and ACE II.
Practical value: the results of the research can be used to improve the tactics of treatment in the presence of diastolic dysfunction associated with insulin resistance, which will permit to reveal the high risk patient in developing of diabetes mellitus.
Practical implementation: the results of the research received academic value appreciation
and have been implemented in the clinical activity of Institute of Cardiology
Under consideration  :